Structure-activity relationships for triphenylethylene antiestrogens on hepatic phase-I and phase-II enzyme expression

Biochemical Pharmacology

Volumn 56, Issue 3, 1998, Pages 321-327

  Nuwaysir, Emile F ^a   Dragan, Yvonne P ^a   McCague, Ray ^b   Martin, Patrice ^c   Mann, John ^c   Jordan, V Craig ^d   Pitot, Henry C ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c UNIVERSITY OF READING   (United Kingdom)

^d NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Antiestrogen; Enzyme induction; Gene expression; Liver; Structure activity relationship; Tamoxifen

Indexed keywords

ANTIESTROGEN; ESTROGEN RECEPTOR; IDOXIFENE; MESSENGER RNA; TAMOXIFEN; TAMOXIFEN DERIVATIVE; TOREMIFENE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL LINE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INDUCTION; FEMALE; GENE REPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER; METABOLIC ACTIVATION; NONHUMAN; NORTHERN BLOTTING; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; RECEPTOR BINDING; RNA ANALYSIS; STRUCTURE ACTIVITY RELATION; TUMOR CELL CULTURE;

ANIMALS; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INDUCTION; ESTROGEN ANTAGONISTS; FEMALE; GLUTATHIONE TRANSFERASE; LIVER; RATS; RATS, INBRED F344; STEROID HYDROXYLASES; STRUCTURE-ACTIVITY RELATIONSHIP; TAMOXIFEN;

EID: 0031659664     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(98)00156-7     Document Type: Article

References (52)

1. Jordan VC, Estrogen/Antiestrogen Action and Breast Cancer Therapy. University of Wisconsin Press, Madison, WI, 1986.
2. Parker M. Structure and function of estrogen receptors. Vitam Horm. 51:1995;267-287.
3. Furr BJ, Jordan VC. The pharmacology and clinical uses of tamoxifen. Pharmacol Ther. 25:1984;127-205.
4. Plowman PN. Tamoxifen as adjuvant therapy in breast cancer. Current status. Drugs. 46:1993;819-833.
5. Sutherland RL, Hall RE, Taylor IW. Cell proliferation kinetics of MCF-7 human mammary carcinoma cells in culture and effects of tamoxifen on exponentially growing and plateau-phase cells. Cancer Res. 43:1983;3998-4006.
6. Sutherland RL, Watts CK, Ruenitz PC. Definition of two distinct mechanisms of action of antiestrogens on human breast cancer cell proliferation using hydroxytriphenylethylenes with high affinity for the estrogen receptor. Biochem Biophys Res Commun. 140:1986;523-529.
7. Rowlands MG, Budworth J, Jarman M, Hardcastle IR, McCague R, Gescher A. Comparison between inhibition of protein kinase C and antagonism of calmodulin by tamoxifen analogues. Biochem Pharmacol. 50:1995;723-726.
8. Lam HY. Tamoxifen is a calmodulin antagonist in the activation of cAMP phosphodiesterase. Biochem Biophys Res Commun. 118:1984;27-32.
9. Rowlands MG, Parr IB, McCague R, Jarman M, Goddard PM. Variation of the inhibition of calmodulin dependent cyclic AMP phosphodiesterase amongst analogues of tamoxifen; correlations with cytotoxicity. Biochem Pharmacol. 40:1990;283-289.
10. 2+-dependent binding of tamoxifen to calmodulin isolated from bovine brain. Cancer Res. 50:1990;2753-2758.
11. McCague R, Rowlands MG, Grimshaw R, Jarman M. Evidence that tamoxifen binds to calmodulin in a conformation different to that when binding to estrogen receptors, through structure-activity study on ring-fused analogues. Biochem Pharmacol. 48:1994;1355-1361.
12. Kiss Z. Tamoxifen stimulates phospholipase D activity by an estrogen receptor-independent mechanism. FEBS Lett. 355:1994;173-177.
13. Colletta AA, Wakefield LM, Howell FV, van Roozendaal KEP, Danielpour D, Ebbs SR, Sporn MB, Baum M. Anti-oestrogens induce the secretion of active transforming growth factor beta from human fetal fibroblasts. Br J Cancer. 62:1990;405-409.
14. 1 in human breast cancer in vivo following tamoxifen treatment. Cancer Res. 52:1992;4261-4264.
15. Bentzen SM, Skoczylas JZ, Overgaard M, Overgaard J. Radiotherapy-related lung fibrosis enhanced by tamoxifen. J Natl Cancer Inst. 88:1996;918-922.
16. Colletta AA, Wakefield LM, Howell FV, Danielpour D, Baum M, Sporn MB. The growth inhibition of human breast cancer cells by a novel synthetic progestin involves the induction of transforming growth factor beta. J Clin Invest. 87:1991;277-283.
17. Knabbe C, Lippman ME, Wakefield LM, Flanders KC, Kasid A, Derynck R, Dickson RB. Evidence that transforming growth factor-β is a hormonally regulated negative growth factor in human breast cancer cells. Cell. 48:1987;417-428.
18. Knabbe C, Zugmaier G, Schmahl M, Dietel M, Lippman ME, Dickson RB. Induction of transforming growth factor β by the antiestrogens droloxifene, tamoxifen, and toremifene in MCF-7 cells. Am J Clin Oncol. 14:(Suppl 2):1991;S15-S20.
19. van den Koedijk CDMA, Vis van Heemst C, Elsendoorn GM, Thijssen JHH, Blankenstein MA. Comparative affinity of steroidal and non-steroidal antioestrogens, cholesterol derivatives and compounds with a dialkylamino side chain for the rat liver antioestrogen binding site. Biochem Pharmacol. 43:1992;2511-2518.
20. van den Koedijk CD, Govers RM, Thijssen JH, Blankenstein MA. Species specificity of triphenylethylene derivatives and of compounds with a steroidal backbone for human and rat liver antioestrogen binding site (AEBS). Biochem Pharmacol. 46:1993;1870-1872.
21. Lazier CB, Bapat BV. Antiestrogen binding sites General and comparative properties . J Steroid Biochem. 31:1988;665-669.
22. Nuwaysir EF, Dragan YP, Jefcoate CR, Jordan VC, Pitot HC. Effects of tamoxifen administration on the expression of xenobiotic metabolizing enzymes in rat liver. Cancer Res. 55:1995;1780-1786.
23. Nuwaysir EF, Daggett DA, Jordan VC, Pitot HC. Phase II enzyme expression in rat liver in response to the antiestrogen tamoxifen. Cancer Res. 56:1996;3704-3710.
24. Hard GC, Iatropoulos MJ, Jordan K, Radi L, Kaltenberg OP, Imondi AR, Williams GM. Major difference in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Crl:CD(BR) rats. Cancer Res. 53:1993;4534-4541.
25. Hirsimaki P, Hirsimaki Y, Nieminen L, Payne BJ. Tamoxifen induces hepatocellular carcinoma in rat liver A 1-year study with two antiestrogens . Arch Toxicol. 67:1993;49-54.
26. Greaves P, Goonetilleke R, Nunn G, Topham J, Orton T. Two-year carcinogenicity study of tamoxifen in Alderley Park Wistar-derived rats. Cancer Res. 53:1993;3919-3924.
27. Williams GM, Iatropoulos MJ, Djordjevic MV, Kaltenberg OP. The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat. Carcinogenesis. 14:1993;315-317.
28. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM. Endometrial cancer in tamoxifen-treated breast cancer patients Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14 [prior annotation incorrect] [see comments] . J Natl Cancer Inst. 86:1994;527-537.
29. Fornander T, Rutqvist LE, Cedermark B, Glas U, Mattsson A, Silfversward C, Skoog L, Somell A, Theve T, Wilking N, Hjalmar M. Adjuvant tamoxifen in early breast cancer Occurrence of new primary cancers . Lancet. 1:1989;117-120.
30. van Leeuwen FE, Benraadt J, Coebergh JW, Kiemeney LA, Gimbrere CH, Otter R, Schouten LJ, Damhuis RA, Bontenbal M, Diepenhorst FW, van den Belt-Dusebout AW, van Tinteren H. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet. 343:1994;448-452.
31. Mani C, Kupfer D. Cytochrome P-450-mediated activation and irreversible binding of the antiestrogen tamoxifen to proteins in rat and human liver Possible involvement of flavin-containing monooxygenases in tamoxifen activation . Cancer Res. 51:1991;6052-6058.
32. Potter GA, McCague R, Jarman M. A mechanistic hypothesis for DNA adduct formation by tamoxifen following hepatic oxidative metabolism. Carcinogenesis. 15:1994;439-442.
33. Phillips DH, Carmichael PL, Hewer A, Cole KJ, Poon GK. α-Hydroxytamoxifen, a metabolite of tamoxifen with exceptionally high DNA-binding activity in rat hepatocytes. Cancer Res. 54:1994;5518-5522.
34. Phillips DH, Hewer A, White IN, Farmer PB. Co-chromatography of a tamoxifen epoxide-deoxyguanylic acid adduct with a major DNA adduct formed in the livers of tamoxifen-treated rats. Carcinogenesis. 15:1994;793-795.
35. Han XL, Liehr JG. Induction of covalent DNA adducts in rodents by tamoxifen. Cancer Res. 52:1992;1360-1363.
36. 32P-postlabeling and use of metabolic inhibitors for two distinct pathways leading to mouse hepatic DNA adduct formation and identification of 4-hydroxytamoxifen as a proximate metabolite . Carcinogenesis. 15:1994;2087-2094.
37. Randerath K, Bi J, Mabon N, Sriram P, Moorthy B. Strong intensification of mouse hepatic tamoxifen DNA adduct formation by pretreatment with the sulfotransferase inhibitor and ubiquitous environmental pollutant pentachlorophenol. Carcinogenesis. 15:1994;797-800.
38. White IN, de Matteis F, Davies A, Smith LL, Crofton-Sleigh C, Venitt S, Hewer A, Phillips DH. Genotoxic potential of tamoxifen and analogues in female Fischer F344/n rats, DBA/2 and C57BL/6 mice and in human MCL-5 cells. Carcinogenesis. 13:1992;2197-2203.
39. Black JW, Duncan WAM, Durant CJ, Ganellin CR, Parsons EM. Definition and antagonism of histamine H2-receptors. Nature. 236:1972;385-390.
40. McCague R, Kuroda R, Leclercq G, Stoessel S. Synthesis and estrogen receptor binding of 6,7-dihydro-8-phenyl-9-[4-[2-(dimethylamino)ethoxy] phenyl]-5H-benzocycloheptene, a nonisomerizable analogue of tamoxifen. X-ray crystallographic studies. J Med Chem. 29:1986;2053-2059.
41. McCague R, Jarman M, Leung OT, Foster AB, Leclercq G, Stoessel S. Non-isomerisable antiestrogens related to tamoxifen. J Steroid Biochem. 31:1988;545-547.
42. McCague R, Leclercq G, Jordan VC. Nonisomerizable analogues of (Z)- and (E)-4-hydroxytamoxifen. Synthesis and endocrinological properties of substituted diphenylbenzocycloheptenes. J Med Chem. 31:1988;1285-1290.
43. McCague R, Leclercq G, Legros N, Goodman J, Blackburn GM, Jarman M, Foster AB. Derivatives of tamoxifen. Dependence of antiestrogenicity on the 4-substituent. J Med Chem. 32:1989;2527-2533.
44. Chander SK, McCague R, Luqmani Y, Newton C, Dowsett M, Jarman M, Coombes RC. Pyrrolidino-4-iodotamoxifen and 4-iodotamoxifen, new analogues of the antiestrogen tamoxifen for the treatment of breast cancer. Cancer Res. 51:1991;5851-5858.
45. Robertson DW, Katzenellenbogen JA, Hayes JR, Katzenellenbogen BS. Antiestrogen basicity-activity relationships A comparison of the estrogen receptor binding and antiuterotrophic potencies of several analogues of (Z)-1,2-diphenyl-1-[4-[2-(dimethylamino)ethoxy]phenyl]-1-butene (tamoxifen, Nolvadex) having altered basicity . J Med Chem. 25:1982;167-171.
46. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanante-phenol-chloroform extraction. Anal Biochem. 162:1987;156-158.
47. Dunn TJ, Koleske AJ, Lindahl R, Pitot HC. Phenobarbital-inducible aldehyde dehydrogenase in the rat. cDNA sequence and regulation of the mRNA by phenobarbital in responsive rats. J Biol Chem. 264:1989;13057-13065.
48. Waxman DJ, Sundseth SS, Srivstava PK, Lapenson DP. Gene-specific oligonucleotide probes for α, μ, π, and microsomal rat glutathione-S-transferases Analysis of liver transferase expression and its modulation by hepatic enzyme inducer and platinum anticancer drugs . Cancer Res. 52:1992;5797-5802.
49. Kawabata TT, Geungerich FP, Baron J. Effects of phenobarbital, trans-stilbene oxide, and 3-methylcholanthrene on epoxide hydrolase within the centrilobular, midzonal, and periportal regions of rat liver. J Biol Chem. 258:1983;7767-7773.
50. Simberg NH, Murai JT, Siiteri PK. In vitro and in vivo binding of toremifene and its metabolites in rat uterus. J Steroid Biochem. 36:1990;197-202.
51. di Salle E, Zaccheo T, Ornati G. Antiestrogenic and antitumor properties of the new triphenylethylene derivative toremifene in the rat. J Steroid Biochem. 36:1990;203-206.
52. Grenman R, Laine KM, Klemi PJ, Grenman S, Hayashida DJ, Joensuu H. Effects of the antiestrogen toremifene on growth of the human mammary carcinoma cell line MCF-7. J Cancer Res Clin Oncol. 117:1991;223-226.